Oryzon considers capital increase before IPO on NASDAQ
Oryzon baraja ampliar capital antes de su salida al NASDAQ
Intel ID : 225290
| Synopsis |
|
Spanish biotechnology company Oryzon Genomics considers a capital increase prior to its plans to go public on the NASDAQ stock market, as reported by newspaper Cinco Dias on 19 May 2015. Recently, the company received EUR 0.236m for research, and now it is in road show with various investors, which may result in a capital increase in the medium term. The objective is to seek financial and industrial partners, which will then follow Oryzon in its process of going public. The company considers this an option, since 50% of all biotechnology companies have gone public with a capital increase. The IPO value was not disclosed.
(content in spanish)
La compañía biotecnológica con sede en España Oryzon Genomics está barajando la posibilidad de llevar a cabo una ampliación de capital previa a su intención de salir al mercado bursátil norteamericano NASDAQ, según ha informado el diario Cinco Días el día 19 de mayo de 2015. La compañía, que recientemente ha recibido EUR 0,236m para investigación, se encuentra en fase de road show con diversos inversores, pudiendo desembocar a medio plazo en una ampliación de capital. La razón principal es buscar previamente socios financieros e industriales, que posteriormente les acompañen en el proceso de comenzar a cotizar. Según la compañía, es una opción, ya que el 50% de empresas biotecnológicas que han dado el salto a la bolsa lo han hecho con una ampliación de capital. Tampoco se conoce el valor con el que Oryzon daría el salto al parqué. |
|
||||
| Intel ID | 225290 | |
| Value | ND | |
| Native Currency | Euro (EUR) | |
|
Financial Data - Oryzon Genomics
(31 Dec 2022) |
Revenue: EUR 15,95m Net Debt: EUR 539,03m People: 44 |
|
| Date |
 |
|
| Country |  |
|
| Region | ||
| Continent | |
|
| Geography | |
|
| Subsector (Old TTR Sectors) |
|
|
| Type |
|
|
| Intel Grade |
|
|
| Source |
|
|
| Tags | |
Target
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.99 Other Biotechnology & Pharmaceuticals 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Secondary Sectors (TTRSC) |
15.06.01 Colleges & Universities 15 Consumer Products & Services / 15.06 Education & Training Services |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Radar
| Date | Title | Type | Intel Grade | Country | Subsector | ||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- |
|
|
|
Mergers & Acquisitions
| Date | Target | Country | Buyer | Seller | VALUE (EURm) | Subsector | |||
|
|
|
|
|
- |
|
|
 |
|
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.